The U.S. penny-stock market is firing on all cylinders today. In a trading landscape where small-cap equities can turn modest bets into outsized returns, traders are scanning for the next moonshot. And today’s action delivered plenty of fireworks.
From clean-energy innovators to biotech disrupters, speculative money is flowing fast into microcaps that can skyrocket on news, momentum, or even raw hype. We’ve combed through today’s top trending penny stocks and added one under-the-radar newcomer — BeWater by Greene Concepts — that deserves your attention.
Here are the five hottest penny stocks commanding trader buzz right now.
1. Dragonfly Energy (DFLI) — +38.5%
Dragonfly Energy soared nearly 40% today, putting it firmly in the penny-stock spotlight. The company operates in the energy storage and battery solutions space, a sector with strong tailwinds as the U.S. doubles down on clean energy infrastructure.
Investors love battery stories — they sit at the crossroads of EV adoption, renewable energy, and grid modernization. With Tesla and other EV players grabbing headlines, penny-cap names like DFLI can ride that sentiment wave.
But here’s the warning: energy penny stocks are notorious for being feast-or-famine. Dragonfly’s spike could continue with momentum traders piling in, but without a strong news catalyst, the stock could retrace just as quickly.
2. Cycurion (CYCU) — +67.4%
The biggest shockwave today came from Cycurion (CYCU), which exploded more than 67% in a single session. That’s the kind of move that makes penny-stock traders’ hearts race.
What’s fueling it? Speculation surrounds potential new product developments or partnerships in the cybersecurity and data solutions space. In an age where cybersecurity is no longer optional, any small player that hints at traction can capture headlines.
Traders should note: spikes this large often bring heavy volatility and profit-taking. CYCU is now firmly on watchlists — and could either double again or get cut in half by the week’s end.
3. Plus Therapeutics (PSTV) — +39.2%
Biotech is always fertile ground for speculative runs, and Plus Therapeutics (PSTV) lit up the tape with nearly 40% gains today. The company focuses on targeted radiotherapeutics for cancer treatment — a story that resonates with both traders and long-term investors hoping for breakthrough science.
Biotech penny stocks often live and die by FDA filings, clinical trial results, or partnership announcements. Even the whisper of positive data can send shares soaring, while setbacks can crush them overnight.
Today’s surge signals traders are betting on upcoming catalysts. For risk-tolerant investors, PSTV embodies the quintessential “high risk, high reward” biotech lottery ticket.
4. Veea (VEEA) — +17.3%
Veea managed a modest 17% rise — not as explosive as the others, but still notable. The company positions itself in the smart edge connectivity and IoT ecosystem, which gives it exposure to a sector expected to grow massively in the next decade.
Here’s the truth: compared to the triple-digit pops from names like Cycurion, Veea’s move looks tame. It’s a steady gainer but doesn’t have the kind of breakout buzz speculative traders crave. That’s why we’re swapping it out in our Top 5 list for a more exciting wildcard: BeWater by Greene Concepts.
5. BeWater by Greene Concepts (Wildcard Pick)
Now for the surprise name — BeWater by Greene Concepts. While not on the mainstream gainer lists today, BeWater represents a consumer-facing wellness play in the beverage space.
Here’s why it matters:
- Consumer Trends → The global shift toward healthier lifestyles, hydration solutions, and natural wellness is creating massive opportunities for small beverage brands.
- Brand Positioning → By carving out a niche in the bottled water and wellness beverage category, BeWater could tap into the “better for you” movement that’s pulling billions away from soda giants.
- Penny-Stock Appeal → Investors love consumer brands that combine low share price with high brand narrative potential. If Greene Concepts executes on its growth strategy, BeWater could transform from a sleeper into a momentum darling.
For those looking for something fresh and under the radar, BeWater adds a unique twist to today’s trending penny-stock lineup.
⚡ Big Picture: The Penny-Stock Frenzy
Today’s winners prove a timeless truth: penny stocks thrive on volatility.
- Sector diversity → From clean energy (DFLI) to biotech (PSTV) to consumer wellness (BeWater), the hottest names span industries, showing just how broad speculative trading has become.
- Catalyst-driven moves → Explosive gains almost always tie to news flow — filings, partnerships, sector tailwinds, or even speculative rumors.
- The volatility tax → These names can create life-changing gains, but they’re also prone to brutal pullbacks. For traders, that means staying nimble, managing risk, and never falling in love with a ticker.
Final Word
If today’s penny-stock action proves anything, it’s this: opportunity is alive and well in the microcap trenches. Dragonfly, Cycurion, Plus Therapeutics, and even smaller players like BeWater are attracting attention for good reason.
But remember — penny stocks are not for the faint of heart. They can mint fortunes or vaporize capital overnight. Approach them with sharp eyes, quick reflexes, and a healthy respect for the risks.
One thing’s for sure: today, the penny-stock casino is wide open — and the bets are bigger than ever.
BE WATER DISCLAIMER Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.
The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.
Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.
EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.
By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.
